Sonde Health and MassGen Selected for MassAITC Pilot Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment

By Business Wire On Feb 28, 2023

Project to leverage vocal biomarkers for cognitive assessment of patients ages 55 and above in home environment

Sonde Health, a health technology company committed to bringing accessible health monitoring to everyone, in conjunction with the Massachusetts General Hospital (MGH) Frontotemporal Disorders (FTD) Unit, has been selected by the Massachusetts Artificial Intelligence and Technology Center for Connected Care in Aging & Alzheimer’s Disease (MassAITC) to lead a pilot study focused on leveraging vocal biomarkers for remote detection and monitoring of mild cognitive impairment in the home environment.

AiThority Interview : AiThority Interview with João Graça, Co-founder and CTO at Unbabel

“By monitoring cognitive health from afar through vocal biomarkers, Sonde’s technology could help facilitate this desire to ‘age in place,’ offering these patients the ability to remain in a familiar environment without sacrificing quality care.”

Funded by MassAITC and the National Institute on Aging (NIA), a division of the U.S. National Institutes of Health (NIH), the project is part of a $1.7 million grant to explore the use of artificial intelligence and other advanced technologies for in-home care. Specifically, it will evaluate the feasibility of obtaining voice recordings of older individuals in the home environment that can be used to longitudinally monitor speech and memory functions.

“Nearly 90% of older adults wish to stay in their homes for as long as possible. Digital technologies, and digital biomarkers in particular, have great potential to support this shift,” said David Liu, CEO of Sonde Health. “By monitoring cognitive health from afar through vocal biomarkers, Sonde’s technology could help facilitate this desire to ‘age in place,’ offering these patients the ability to remain in a familiar environment without sacrificing quality care.”

The project will enroll 50 adults from the FTD Unit. Participants will be ages 55 and above and represent a range of cognitive function from normal cognition through subjective cognitive decline, mild cognitive impairment (MCI), and mild dementia. The longitudinal study will examine the potential for Sonde’s vocal biomarker platform to monitor and detect changes in cognitive function for individuals at home. Participants will record 10-15 different voice samples and responses to cognitive assessments both in the laboratory setting and from their personal smartphones at home. Voice recordings will be analyzed for acoustic features that correlate with mental status, which are expected to provide insights into how vocal biomarkers can be used as an effective tool for tracking cognitive health over time.

The pilot is part of MassAITC’s larger mission to realize the goal of aging at home through interdisciplinary research. It will serve as an important reference data set to further test and validate vocal biomarkers relevant to the detection or monitoring of cognitive impairment. This study builds on several current Sonde projects focused on testing cognitive biomarkers, including a multi-year strategic partnership with GN Group to research and develop commercial vocal biomarkers for MCI.

“As the population of older adults continues to grow, there is a critical need for remote monitoring technologies that can detect cognitive impairment early and accurately,” said Deepak Ganesan, Director of the MassAITC. “By supporting a study that combines Sonde Health’s vocal biomarker technology and Massachusetts General Hospital’s expertise in clinical dementia research, we believe we’re one step closer to developing the tools and resources needed to elevate aging-in-place care models.”

“With this pilot study, we are excited to partner with Sonde Health to contribute new insights into how voice-based remote monitoring of cognitive function for older adults will potentially augment specialized clinical evaluations,” said Brad Dickerson, MD, Director of the MGH Frontotemporal Disorders Unit and Professor of Neurology at Harvard Medical School.

Latest Interview Insights : AiThority Interview with Ritu Bhargava, Chief Product Officer at SAP CX

[To share your insights with us, please write to sghosh@martechseries.com]